Vizamyl (Flutemetamol F 18 Injection)

Electronic Reader Training Program

This online program was based on the European Vizamyl (Flutemetamol F18) Summary of Products Characteristics (SmPC). There are certain differences between the Swiss Package Insert (PI) and the European SmPC due to the national marketing authorization issued by Swissmedic.

This electronic training contains important information to ensure accurate and reliable interpretation of PET imagines when using Vizamyl and serves as additional risk reduction measures to provide guidance to healthcare professionals. Side effects associated with the use of Vizamyl should be reported via electronic exchange to the Safety of Medicines Division, Risk Management Unit Swissmedic.

Please review the Swiss Vizamyl PI on Swissmedicinfo before you continue.

By continuing you agree that you have read and understood the Swiss PI.